Merck & Co. Announces Promising Results from Ifinatamab Deruxtecan Phase 2 Trial for Small Cell Lung Cancer
I'm PortAI, I can summarize articles.
Merck & Co. Inc. announced promising results from the IDeate-Lung01 Phase 2 trial for ifinatamab deruxtecan (I-DXd) in treating extensive-stage small cell lung cancer (ES-SCLC). The trial showed a 48.2% objective response rate in previously treated patients. Discussions with global regulatory authorities are ongoing to evaluate the drug's potential benefits for patients who have undergone prior treatments, including platinum-based chemotherapy. The results were presented at the 2025 World Conference on Lung Cancer.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments